Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 34NIH 27INDUSTRY 6OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 3Leukemia 3Burkitt Lymphoma 3Solid Tumors 1Solid Tumor 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Hematologic Neoplasms 1Hematologic Diseases 1Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited 1

Interventions

Interleukin-2 4Nivolumab 3Melphalan 3pembrolizumab 2tremelimumab 1tislelizumab 1fludarabine 1encorafenib 1binimetinib 1apatinib 1Tramadol 1Technetium 1Surgical Procedures, Operative 1Metastasectomy 1Ipilimumab 1Immunotherapy 1Ibuprofen 1Fecal Microbiota Transplantation 1FMT protocol 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Melanoma × fludarabine × Clear all
NCT03166397 2023-01-26

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Sheba Medical Center

Phase 2 Unknown
30 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡